Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenus
2
0
0
0
0
0
Croissance des revenus (H/H)
--
--
--
--
--
--
Coût des ventes
2
--
--
--
--
--
Bénéfice brut
0
--
--
--
--
--
Vente, Général et Administration
117
7
8
6
2
1
Recherche et développement
0
0
1
2
1
0
Frais d'exploitation
117
7
9
8
4
2
Autres revenus (charges) non opérationnels
3
-1
0
0
--
--
Bénéfice avant impôts
-104
-9
-9
-4
-4
-2
Charge d'impôt sur le revenu
--
0
0
--
--
--
Bénéfice net
-104
-9
-9
-4
-4
-2
Croissance du bénéfice net
1,386%
0%
125%
0%
100%
0%
Actions en circulation (diluées)
24.34
0
0
0
0
0
Variation des actions (H-H)
553,105%
110%
67%
-14%
0%
0%
EPS (dilué)
-4.28
-2,218.66
-4,995.75
-3,772.35
-3,352.51
-1,683.45
Croissance du EPS
-100%
-56%
32%
13%
99%
14%
Flux de trésorerie libre
-16
-7
-9
-9
-5
-2
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
0%
--
--
--
--
--
Marge opérationnelle
-5,850%
0%
0%
0%
0%
0%
Marge bénéficiaire
-5,200%
0%
0%
0%
0%
0%
Marge du flux de trésorerie libre
-800%
0%
0%
0%
0%
0%
EBITDA
-117
-7
-9
-8
-4
-2
Marge EBITDA
-5,850%
0%
0%
0%
0%
0%
D&A pour le résultat opérationnel
0
0
0
0
0
0
EBIT
-117
-7
-9
-8
-4
-2
Marge EBIT
-5,850%
0%
0%
0%
0%
0%
Taux d'imposition effectif
--
0%
0%
--
--
--
Statistiques clés
Clôture préc.
$1.66
Prix d'ouverture
$1.63
Plage de la journée
$1.62 - $1.71
Plage de 52 semaines
$1.41 - $211.2
Volume
153.3K
Volume moyen
555.4K
BPA (TTM)
-689.87
Rendement en dividend
--
Capitalisation boursière
$47.4M
Qu’est-ce que STSS ?
Sharps Technology, Inc. is a medical device and pharmaceutical packaging company, which engages in the development and manufacturing of innovative drug delivery systems. The company is headquartered in Melville, New York and currently employs 5 full-time employees. The company went IPO on 2022-04-14. The firm is engaged in offering patented smart-safety syringe products to the healthcare industry. The firm's smart safety syringe products, such as Securgard, Sologard, and Sharps Provensa, are ultra-low waste syringes that incorporate both passive and active safety and reuse prevention features. The company Sharps Securegard and Sologard safety syringe product lines incorporate both active and passive safety features and have been designed to address the primary administration concerns with syringe delivery systems, including accidental needlestick injuries, wasted medicine/dead space and reuse prevention. The company also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The company has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the United States.